Emma is doing something she swore she never would - buying her kids vapes
A tiny implant just helped paralyzed rats walk again—is human recovery next?
Spinal cord injuries are currently incurable with devastating effects on people's lives, but now a trial at Waipapa Taumata Rau, University of Auckland offers hope for an effective treatment.
Spinal cord injuries shatter the signal between the brain and body, often resulting in a loss of function."Unlike a cut on the skin, which typically heals on its own, the spinal cord does not regenerate effectively, making these injuries devastating and currently incurable," says lead researcher Dr Bruce Harland, a senior research fellow in the School of Pharmacy at Waipapa Taumata Rau, University of Auckland.
Before birth, and to a lesser extent afterwards, naturally occurring electric fields play a vital role in early nervous system development, encouraging and guiding the growth of nerve tissue along the spinal cord. Scientists are now harnessing this same electrical guidance system in the lab.An implantable electronic device has restored movement following spinal cord injury in an animal study, raising hopes for an effective treatment for humans and even their pets.
"We developed an ultra-thin implant designed to sit directly on the spinal cord, precisely positioned over the injury site in rats," Dr Harland says.
The device delivers a carefully controlled electrical current across the injury site. "The aim is to stimulate healing so people can recover functions lost through spinal-cord injury," Professor Darren Svirskis, director of the CatWalk Cure Program at the University's School of Pharmacy says.
Unlike humans, rats have a greater capacity for spontaneous recovery after spinal cord injury, which allowed researchers to compare natural healing with healing supported by electrical stimulation.
After four weeks, animals that received daily electric field treatment showed improved movement compared with those who did not.
Throughout the 12-week study, they responded more quickly to gentle touch.
"This indicates that the treatment supported recovery of both movement and sensation," Harland says. "Just as importantly, our analysis confirmed that the treatment did not cause inflammation or other damage to the spinal cord, demonstrating that it was not only effective but also safe."
This new study, published in Nature Communications, has come out of a partnership between the University of Auckland and Chalmers University of Technology in Sweden.
"Long term, the goal is to transform this technology into a medical device that could benefit people living with these life-changing spinal-cord injuries," says Professor Maria Asplund of Chalmers University of Technology.
"This study offers an exciting proof of concept showing that electric field treatment can support recovery after spinal cord injury," says doctoral student Lukas Matter, also from Chalmers University.
The next step is to explore how different doses, including the strength, frequency, and duration of the treatment, affect recovery, to discover the most effective recipe for spinal-cord repair.
Scientists turn beer yeast into mini factories for smart drugs
Scientists at Ca' Foscari University of Venice, in collaboration with researchers from Japan, China, Switzerland, and Italy, have developed an innovative method to produce and rapidly analyze a vast array of macrocyclic peptides, molecules increasingly used in modern medicine. The research, published in Nature Communications, harnesses the familiar brewer's yeast, turning billions of these tiny organisms into miniature fluorescent factories, each capable of creating a unique peptide with potential therapeutic applications.
Macrocyclic peptides are promising drugs because they combine precision targeting, stability, and safety, offering fewer side effects than traditional drugs. However, conventional methods for discovering and testing these peptides are often complex, difficult to control, slow, and environmentally unfriendly.
To overcome these limitations, the researchers engineered common brewer's yeast cells to individually produce different macrocyclic peptides. Each yeast cell acts like a tiny factory that lights up when prod-ucing the compound, allowing scientists to swiftly identify promising peptides. Using advanced fluorescence-based techniques, the team screened billions of these micro-factories in just a few hours, a process that is significantly faster and more ecofriendly than existing methods.
Sara Linciano, lead author and postdoctoral researcher at Ca' Foscari's Department of Molecular Sciences and Nanosystems, explains: "We manipulated yeast cells so that each one functions as a 'micro-factory' that becomes fluorescent when producing a specific compound. This allowed us to analyze 100 million different peptides rapidly and effectively."
Ylenia Mazzocato, co-leader of the study, highlights the sustainability of their approach: "By exploiting the natural machinery of yeast, we produce peptide molecules that are biocompatible and biodegradable, making them safe for health and the environment, a truly 'green pharma' approach."
The team also clarified how these peptides precisely bind to their targets. Zhanna Romanyuk, who contributed to the structural analysis, says: "Using X-ray crystallography, we demonstrated the excellent binding properties of these peptides, confirming their precision and potency."
This new method offers significant advancements for drug discovery, especially for challenging targets that conventional drugs cannot easily address. Alessandro Angelini, associate professor and study coordinator, emphasizes: "We are pushing the boundaries of this technology to create macrocyclic peptides that can deliver advanced therapies directly to specific cells, potentially revolutionising treatments. This could greatly benefit patient health and have substantial scientific and economic impacts."
This work was part of the National Recovery and Resilience Plan (PNRR), supported by the European Union's Next Generation EU initiative, involving multidisciplinary teams from Ca' Foscari University of Venice, Kyoto Institute of Technology (KIT), Chinese Academy of Sciences, University of Padova, and École Polytechnique Fédérale de Lausanne (EPFL), including experts in chemistry, biophysics, biochemistry, and computational sciences.
Part of this technology has already been patented by Ca' Foscari and was recently acquired by the startup Arzanya S.r.l. "Seeing our technology gain international recognition makes me proud," Angelini concludes. "I I hope Arzanya S.r.l. can provide our talented young researchers with the opportunity to pursue their passions here in Italy, without necessarily needing to move abroad."